Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Synlogic Q3 2026 Results: Net Loss of $3.87M, Loss Widens

Synlogic, Inc. reported a net loss of $3.9 million for the third quarter of 2026, compared to $2.3 million in the prior year, primarily driven by restructuring and transaction-related charges. The company has discontinued its clinical trials and entered into a merger agreement with Caldera Therapeutics, Inc. as part of a strategic review process. As of September 30, 2026, the company held $11.6 million in cash and cash equivalents.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.00.0
Net income-3.9-2.3
EPS (diluted, $ a share)$-0.31$-0.19

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, OTC: SYBX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Synlogic, Inc.: key numbers

Share price
$1.10Close, Nov 13
Market cap
$13.5M
Shares outstanding
12.25MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.